Events

Kamada Virtual Analyst Day

May 25, 2022

The analyst day will feature presentations from Amir London (Chief Executive Officer), Chaime Orlev (Chief Financial Officer), and Jon R. Knight (Vice President, U.S. Commercial Operations) who will discuss Kamada’s strategic evolution into a fully-integrated specialty plasma company with six FDA-approved products and strong commercial capabilities in the U.S. market, as well as a global commercial footprint in over 30 countries. The…

Read More

Satsuma Pharmaceuticals: KOL Event on the Acute Treatment of Migraine, DHE and STS101

May 19, 2022

The webinar will feature presentations from Key Opinion Leaders (KOL’s) Amaal J. Starling, M.D. (Mayo Clinic College of Medicine and Science) and Stewart J. Tepper, M.D. (Geisel School of Medicine at Dartmouth University) who will discuss the current treatment landscape and unmet medical need in treating patients suffering from migraines. Satsuma’s STS101, dihydroergotamine nasal powder, will…

Read More

RYVU Therapeutics: KOL Event on RVU120: A First-in-Class CDK8/19i in Phase I Studies for Hematological Malignancies and Solid Tumors

May 18, 2022

The webinar will feature a presentation from Key Opinion Leader (KOL) Dr. Michael Savona, MD (Vanderbilt University School of Medicine) who will discuss the current treatment landscape and unmet medical needs in treating patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The Ryvu Therapeutics leadership team will discuss the underlying mechanism of action of…

Read More

NOXXON Pharma: KOL Webinar on GLORIA Top-Line Results of NOX-A12 & Radiotherapy Combination in First-Line Glioblastoma Presented at ASCO 2022

May 18, 2022

The webinar will feature a presentation from Frank A. Giordano, M.D. (Chair, Department of Radiation Oncology, University Hospital Bonn, Germany), who will present and discuss the top-line results of the GLORIA Phase 1/2 trial evaluating NOX-A12 in combination with radiotherapy in patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. The webinar will follow Dr. Giordano’s poster presentation at…

Read More

Aptose Biosciences KOL Data Call on HM43239 and Luxeptinib: Potential Treatment Candidates for AML

May 13, 2022

The data call will feature Key Opinion Leaders (KOL’s) Brian Druker, M.D. (Oregon Health & Science University), Naval G. Daver, M.D. (MD Anderson Cancer Center) and Brian Andrew Jonas, M.D., Ph.D. (University of California, Davis) who will discuss the current treatment landscape and unmet medical need in treating patients with acute myeloid leukemia (AML). The Aptose leadership team will…

Read More

KOL Event on Tenax’s TNX-201 (imatinib): A Potential Treatment for Pulmonary Arterial Hypertension

May 13, 2022

The webinar will feature presentations from Key Opinion Leaders (KOL’s) Anna Hemnes, MD (Vanderbilt University Medical Center), John Ryan, MD, MB, BCH, BAO (University of Utah), Bradley Maron, MD (Harvard Medical School), and Robert Frantz, MD, FACC (Mayo Clinic College of Medicine) The discussion will focus on the current treatment landscape and unmet medical need in treating patients…

Read More

Virtual KOL Breakfast on Valneva’s Chikungunya Vaccine Candidate (pre-BLA stage)

May 10, 2022

FULLY VIRTUAL Wednesday, May 25, 2022 Presentations: 7:30 – 8:30 AM ET / 1:30 – 2:30 PM CEST Join us for a virtual live event featuring Key Opinion Leader and Travel and Tropical Medicine expert Bradley A. Connor, M.D. (Weill Cornell Medical College, New York Presbyterian), who will discuss the unmet medical need to protect travelers and prevent…

Read More

KOL Event on Quotient’s MosaiQ™ Solution

May 6, 2022

The webinar will feature a presentation from Key Opinion Leader (KOL) Christophe Martinaud, MD, PhD who will discuss the current treatment landscape and unmet need in blood grouping and donor disease screening. The Quotient team will present their MosaiQ solution, designed to provide multimodal, multiplexed testing on a fully automated platform, delivering clinical and economic value to customers,…

Read More

KOL Webinar on VYNE’s BET Inhibitor Platform

May 6, 2022

The VYNE Therapeutics KOL Webinar will feature a presentation from Gerald V. Denis, PhD (Boston University School of Medicine) and Thierry Passeron, MD, PhD (University Hospital of Nice). Dr. Denis will provide a background on pan-bromodomain and extra-terminal (“BET”) inhibition for the treatment of various immuno-inflammatory conditions, and Dr. Passeron will then discuss the current treatment landscape…

Read More

MindMed KOL Webinar on Substance Use Disorders & Withdrawal Management

May 4, 2022

The webinar will feature presentations from Key Opinion Leaders (KOLs) Kelly E. Dunn, PhD, MBA (Johns Hopkins School of Medicine) and Stuart Gitlow, MD, MPH, MBA (Past President of the American Society of Addiction Medicine) who will discuss substance use disorders, the current treatment landscape for opioid use disorder, and unmet medical need in the management of opioid withdrawal.…

Read More